when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

WAINUA (AUTOINJECTOR) · news · pharmadog

← back to WAINUA (AUTOINJECTOR)

News mentioning WAINUA (AUTOINJECTOR)

29 stories

19dIonis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSbiospace

26d5 biotechs braving the commercial waters with product launchesbiospace

Sep 8, 26Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’biospace

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Aug 31, 26STAT+: Trump strikes nine more deals with drugmakers to lower pricesstat

Aug 31, 26ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CMfiercebiotech

Aug 31, 26STAT+: Can a pregnancy hormone steer a cardiovascular treatment?stat

Aug 31, 26STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapystat

Aug 31, 26STAT+: After a rough stretch, mRNA gets a boost — at least for nowstat

Aug 30, 26STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancerstat

Aug 30, 26STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainuastat

Aug 28, 26‘Worse than expected’ Wainua data muddies water for TTR silencersbiospace

Aug 28, 26#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencerendpoints

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 12, 26BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectationsbiospace

Aug 7, 26Intellia finds genetic suspect for liver safety signals with ATTR gene therapybiospace

Aug 3, 26‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everbiospace

Aug 3, 265 companies advancing ATTR assets in the wake of Wainua’s failbiospace

Jul 31, 26Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchisebiospace

Jul 29, 26Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, morebiospace

Jul 27, 26AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failurebiospace

Jul 22, 26Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2biospace

Jul 22, 26Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugfiercebiotech

Jul 22, 26Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsbiospace

Jul 9, 26STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and morestat

Jul 9, 26STAT+: AstraZeneca, Ionis report major trial failure with heart disease drugstat

Jul 9, 26Updated: AstraZeneca sinks on unexpected heart drug trial failureendpoints

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive